000756 新华制药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.4239.84911.44110.82610.417
总资产报酬率 ROA (%)2.4515.4326.0005.2714.833
投入资产回报率 ROIC (%)3.0506.6937.4226.6316.113

边际利润分析
销售毛利率 (%)20.03824.11429.52427.15427.037
营业利润率 (%)5.6966.3126.5996.3546.488
息税前利润/营业总收入 (%)5.8946.4476.7786.7157.228
净利润/营业总收入 (%)4.9835.7496.2485.6795.519

收益指标分析
经营活动净收益/利润总额(%)112.06798.566106.994102.27591.717
价值变动净收益/利润总额(%)2.2311.8431.7991.7731.903
营业外收支净额/利润总额(%)-0.273-0.134-0.356-1.045-1.034

偿债能力分析
流动比率 (X)1.2661.3331.3331.0941.101
速动比率 (X)0.8770.8780.8050.7110.690
资产负债率 (%)41.92342.15442.36547.37250.203
带息债务/全部投入资本 (%)26.84828.88728.63335.11224.727
股东权益/带息债务 (%)260.761235.109237.510175.807245.469
股东权益/负债合计 (%)132.383131.285129.703105.39094.215
利息保障倍数 (X)27.67844.95633.57815.7348.962

营运能力分析
应收账款周转天数 (天)38.10833.33932.46634.06228.494
存货周转天数 (天)60.70272.44679.60873.75480.926